# Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

> **NCT01292460** · PHASE3 · COMPLETED · sponsor: **Santen Oy** · enrollment: 600 (estimated)

## Conditions studied

- Ocular Hypertension
- Open-angle Glaucoma

## Interventions

- **DRUG:** Timolol/ FDC/ Placebo/ Tafluprost

## Key facts

- **NCT ID:** NCT01292460
- **Lead sponsor:** Santen Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2013-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01292460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01292460, "Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01292460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*